Opzelura Wins Second EU Indication, Analysts Lift Incyte Targets
INCY sits 66% above its 52-week low of $73.805.
Summary
Opzelura secured a second EU indication based on Phase 3b data showing sustained EASI-75 and IGA-TS improvements through week 24. This expands the drug's addressable market in atopic dermatitis, a key growth driver. The news follows last week's strong Q2 results and raised guidance, and prompted analysts at Guggenheim, HC Wainwright, Barclays, and Leerink to lift price targets to $139–$155. The regulatory win and analyst endorsements reinforce the commercial momentum behind Opzelura.
At the time of this announcement, INCY was trading at $122.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.2B. The 52-week trading range was $73.81 to $132.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.